Abstract
Mutations in mitochondrial genes, oxidative insults, imbalance in redox mechanisms and dysregulated mitophagy are some of the leading causes for mitochondrial dysfunction and subsequent neurodegeneration in Parkinson’s disease. Targeting mitochondrial dysfunction and prolonging neuronal survival could potentially prove to be useful neuroprotective strategies. In some recent investigations, peroxisome proliferator activated receptor gamma coactivator 1 alpha mediated mitochondrial biogenesis and its ability to restore reactive oxygen species-detoxifying enzymes have been observed in preclinical studies. In this review, we discuss about physiological importance of peroxisome proliferator activated receptor gamma coactivator 1 alpha along with a list of its activators that could prove useful as possible neuroprotectants in Parkinson’s disease.
Keywords: Mitochondrial biogenesis, Mitochondrial transcription factor A, Neurodegeneration, Parkinson’s disease, Reactive oxygen species, Sirtuin 1.
CNS & Neurological Disorders - Drug Targets
Title:Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
Volume: 14 Issue: 8
Author(s): Nihar Ranjan Das and Shyam Sunder Sharma
Affiliation:
Keywords: Mitochondrial biogenesis, Mitochondrial transcription factor A, Neurodegeneration, Parkinson’s disease, Reactive oxygen species, Sirtuin 1.
Abstract: Mutations in mitochondrial genes, oxidative insults, imbalance in redox mechanisms and dysregulated mitophagy are some of the leading causes for mitochondrial dysfunction and subsequent neurodegeneration in Parkinson’s disease. Targeting mitochondrial dysfunction and prolonging neuronal survival could potentially prove to be useful neuroprotective strategies. In some recent investigations, peroxisome proliferator activated receptor gamma coactivator 1 alpha mediated mitochondrial biogenesis and its ability to restore reactive oxygen species-detoxifying enzymes have been observed in preclinical studies. In this review, we discuss about physiological importance of peroxisome proliferator activated receptor gamma coactivator 1 alpha along with a list of its activators that could prove useful as possible neuroprotectants in Parkinson’s disease.
Export Options
About this article
Cite this article as:
Das Ranjan Nihar and Sharma Sunder Shyam, Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150326000018
DOI https://dx.doi.org/10.2174/1871527314666150326000018 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interaction of Biologically Active Amines with Mitochondria and Their Role in the Mitochondrial-Mediated Pathway of Apoptosis
Current Medicinal Chemistry Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Identification of Fish Cell Lines Using 2-D Electrophoresis Based Protein Expression Signatures
Current Proteomics 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology A Step Further Towards Multitarget Drugs for Alzheimer and Neuronal Vascular Diseases: Targeting the Cholinergic System, Amyloid-β Aggregation and Ca2++ Dyshomeostasis
Current Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Decision Support System for Lymphoma Classification
Current Medical Imaging Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Synthesis and Biological Evaluation of Naloxone and Naltrexone-Derived Hybrid Opioids
Medicinal Chemistry Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters